NCT	Phase	Conditions	Drugs	BriefTitle	OfficialTrial	Oncotree Codes
NCT00321685	2	Rectal Adenocarcinoma|Stage II Rectal Cancer AJCC v7|Stage III Rectal Cancer AJCC v7	Capecitabine|Fluorouracil|Leucovorin Calcium|Oxaliplatin	Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer	Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer	READ|MT|CHOL
NCT00392327	3	Anaplastic Medulloblastoma|Medulloblastoma|Untreated Childhood Medulloblastoma	Carboplatin|Cisplatin|Cyclophosphamide|Isotretinoin|Vincristine Sulfate	Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma	Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients	AMBL|MBL
NCT00492778	2	Endometrial Adenocarcinoma|Endometrial Adenosquamous Carcinoma|Endometrial Clear Cell Adenocarcinoma|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation|Endometrial Serous Adenocarcinoma|Recurrent Uterine Corpus Carcinoma	Cisplatin	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	CEEN|MT|UTERUS|UEC|USC
NCT00601003	2	Neuroblastoma|Medulloblastoma	Nifurtimox|Cyclophosphamide|Topotecan	Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma	A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.	MBL|NBL
NCT00632853	3	Lung Cancer	cisplatin|etoposide|carboplatin	Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide	NSCLC|MT|LUAS|SCLC|LCLC|LUNG|LUSC|NSCLCPD|CSCLC
NCT00887146	3	Brain and Central Nervous System Tumors	concomitant temozolomide (TMZ)|procarbazine|adjuvant temozolomide (TMZ)|CCNU|vincristine	Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma	Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	BRAIN
NCT00980954	3	Cervical Cancer	carboplatin|cisplatin|paclitaxel	Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy	MT|UUC|ECAD|CESC
NCT01042522	2	Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor	Carboplatin|Cisplatin|Etoposide Phosphate|Paclitaxel	Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors	A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary	GRCT|SLCT|SYNS|ES|SCST|EPIS
NCT01101451	3	Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IA Cervical Cancer|Stage IB Cervical Cancer|Stage IIA Cervical Cancer	Cisplatin	Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy	OTHER|MT|CEAS|CEAD|CESC
NCT01349881	3	Colorectal Neoplasms	Eflornithine placebo & sulindac placebo|eflornithine & sulindac placebo|Eflornithine placebo & sulindac|Eflornithine plus sulindac	S0820, Adenoma and Second Primary Prevention Trial	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)	
NCT01503632	3	Childhood Acute Lymphoblastic Leukemia in Remission	Mercaptopurine	Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission	A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL	LYMPH|SYNS
NCT01553071	1	Solid Tumor	Fenretinide (4-HPR) plus Intravenous Safingol	Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies	Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies	
NCT01595061	2	Stage IIIA Vulvar Cancer AJCC v7|Stage IIIB Vulvar Cancer AJCC v7|Stage IIIC Vulvar Cancer AJCC v7|Stage IVA Vulvar Cancer AJCC v7|Vulvar Squamous Cell Carcinoma	Cisplatin|Gemcitabine Hydrochloride	Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva	A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)	VULVA|MT|CHOL
NCT01602666	2	Central Nervous System Nongerminomatous Germ Cell Tumor|Childhood Central Nervous System Germinoma	Carboplatin|Etoposide|Ifosfamide	Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors	Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT)	BRAIN|GMN
NCT01614197	1	Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Lymphoma|Peripheral T-cell Lymphoma	Temsirolimus|Etoposide|Etoposide|Cyclophosphamide|Methotrexate|Hydrocortisone|Cytarabine	A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma	A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma	MTNN|MLYM|LYMPH|NPTLTFH|PTCL
NCT01659658	3	Relapsed or Refractory Systemic Light Chain Amyloidosis	IXAZOMIB|Dexamethasone|Melphalan|Cyclophosphamide|Thalidomide|Lenalidomide	Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis	A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis	MIDDA
NCT01674140	3	Breast Cancer	anastrozole|everolimus|exemestane|goserelin acetate|letrozole|leuprolide acetate|tamoxifen citrate	S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer	MMBC|IMMC|MT|EMBC|IBC|MBC|BREAST|ACBC|BRCA
NCT01744223	1/Phase 2	Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoma		Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant	A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)	MLYM|LYMPH|AML
NCT01803282	1	Tumors|Pancreatic Cancer|Non-small Cell Lung Cancer|Esophagogastric Cancer|Colorectal Cancer|Breast Cancer	Andecaliximab|Gemcitabine|Nab-paclitaxel|Carboplatin|Pemetrexed|Leucovorin|Oxaliplatin|5-FU|Bevacizumab|Irinotecan|Paclitaxel	Safety and Tolerability Study in Solid Tumors	A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors	GINET|STOMACH|PANET|IMMC|MBC|LUNG|BREAST|NSCLC|MMBC|EMBC|IBC|PCNSMT|MT|SCLC|DCS|PRNET|GINETES|SWDNET|NSCLCPD|ES|EPIS|ACBC|BRCA
NCT01818986	2	Metastatic Castrate-resistant Prostate Cancer|mCRPC	Sipuleucel-T	Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)	Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)	PROSTATE|MT|ES|EPIS
NCT01878617	2	Medulloblastoma	Cyclophosphamide|Cisplatin|Vincristine|Vismodegib|Pemetrexed|Gemcitabine	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma	MBL
NCT01926197	3	Pancreatic Cancer	Oxaliplatin|Irinotecan|Leucovorin|5FU	Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer	A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer	MT
NCT01953588	3	Estrogen Receptor-positive Breast Cancer|HER2-negative Breast Cancer|Invasive Ductal Breast Carcinoma|Invasive Lobular Breast Carcinoma|Recurrent Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer	fulvestrant|anastrozole	Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery	Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study	ILC|BREAST|MT|IDC|ES|EPIS
NCT01956669	2	Solid Tumours	Pazopanib GW786034	Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors	A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors	
NCT01962896	2	Relapsed / Recurrent Germ Cell Tumors	Erlotinib|Sirolimus	A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors	A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors	
NCT01979536	2	Anaplastic Large Cell Lymphoma, ALK-Positive|Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma|Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma|CD30-Positive Neoplastic Cells Present	Brentuximab Vedotin|Crizotinib|Cyclophosphamide|Cytarabine|Dexamethasone|Doxorubicin Hydrochloride|Etoposide|Ifosfamide|Methotrexate	Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma	A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)	LYMPH|MLYM|ALCL|RBL|ES|EPIS
NCT02003222	3	Acute Lymphoblastic Leukemia|B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative|BCR/ABL1 Fusion Protein Negative|Untreated Adult Acute Lymphoblastic Leukemia	Cyclophosphamide|Cytarabine|Daunorubicin Hydrochloride|Dexamethasone|Etoposide|Mercaptopurine|Methotrexate|Pegaspargase|Prednisone|Vincristine Sulfate	Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults	LYMPH
NCT02013336	1	Recurrent or Refractory Solid Tumors|Ewing Sarcoma|Rhabdomyosarcoma|Neuroblastoma|Osteosarcoma	MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide	Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors	Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors	OS|RMS|NBL|ES
NCT02043665	1	Non-small Cell Lung Cancer|Bladder Cancer		CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)	A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)	LUNG|GBC|BLADDER|NSCLC|MT|SCBC|SCLC|NSCLCPD
NCT02064673	3	Prostate Cancer	Curcumin|placebo	Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy	Randomized Trial of Adjuvant Curcumin After Prostatectomy	PROSTATE|MT
NCT02065869	1/Phase 2	Acute Lymphoblastic Leukemia|Leukemia, Acute Myeloid (AML), Child|Lymphoma, Non-Hodgkin|Myelodysplastic Syndrome|Immunologic Deficiency Syndromes	AP1903	Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant	Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR Î±Î²+T Cells in Pediatric Patients Affected by Hematological Disorders	LYMPH|MDS|MLYM|MYELOID|AML|ES|EPIS
NCT02092324	2	Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Neutrophilic Leukemia	Ruxolitinib Phosphate	Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia	Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R	CNL|CML|MYELOID|MT
NCT02098343	1/Phase 2	Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53	APR-246|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)	p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246	HGSOC|MT|SOC|HTAT
NCT02101853	3	B Acute Lymphoblastic Leukemia	Asparaginase|Cyclophosphamide|Cytarabine|Dexamethasone|Etoposide|Leucovorin Calcium|Mercaptopurine|Methotrexate|Mitoxantrone Hydrochloride|Pegaspargase|Therapeutic Hydrocortisone|Thioguanine|Vincristine Sulfate	Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia	Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	LYMPH
NCT02112916	3	Adult T Acute Lymphoblastic Leukemia|Ann Arbor Stage II Adult Lymphoblastic Lymphoma|Ann Arbor Stage II Childhood Lymphoblastic Lymphoma|Ann Arbor Stage III Adult Lymphoblastic Lymphoma|Ann Arbor Stage III Childhood Lymphoblastic Lymphoma|Ann Arbor Stage IV Adult Lymphoblastic Lymphoma|Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma|Childhood T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia	Bortezomib|Cyclophosphamide|Cytarabine|Daunorubicin Hydrochloride|Dexamethasone|Doxorubicin Hydrochloride|Etoposide|Hydrocortisone Sodium Succinate|Ifosfamide|Leucovorin Calcium|Mercaptopurine|Methotrexate|Pegaspargase|Thioguanine|Vincristine Sulfate	Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma	A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)	LYMPH|MLYM|RBL
NCT02115282	3	Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7	Entinostat|Exemestane|Goserelin Acetate	Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic	A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer	CHOL|BREAST|MT|ES|EPIS
NCT02135042	2/Phase 3	Epstein-Barr Virus Infection|Stage II Nasopharyngeal Carcinoma|Stage III Nasopharyngeal Carcinoma|Stage IVA Nasopharyngeal Carcinoma|Stage IVB Nasopharyngeal Carcinoma	Cisplatin|Fluorouracil|Gemcitabine Hydrochloride|Paclitaxel	Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	NPC|MT
NCT02152982	2/Phase 3	Glioblastoma|Gliosarcoma	Temozolomide|Veliparib	Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation	GB|GSARC
NCT02154490	2/Phase 3	Recurrent Squamous Cell Lung Carcinoma|Stage IV Squamous Cell Lung Carcinoma AJCC v7	Docetaxel|Erlotinib Hydrochloride|FGFR Inhibitor AZD4547|Palbociclib|Talazoparib|Taselisib	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)	CHOL|LUNG|LUSC|MT
NCT02155920	2	Recurrent Childhood Ependymoma	Everolimus	Everolimus for Children With Recurrent or Progressive Ependymoma	Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma	EPM
NCT02163356	1	Recurrent Neuroblastoma|Neuroblastoma	Fenretinide/LXS Oral Powder|Ketoconazole|Vincristine	Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma	Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254)	NBL
NCT02166463	3	Ann Arbor Stage IIB Hodgkin Lymphoma|Ann Arbor Stage IIIB Hodgkin Lymphoma|Ann Arbor Stage IV Hodgkin Lymphoma|Ann Arbor Stage IVA Hodgkin Lymphoma|Ann Arbor Stage IVB Hodgkin Lymphoma|Childhood Hodgkin Lymphoma|Classic Hodgkin Lymphoma	Brentuximab Vedotin|Cyclophosphamide|Doxorubicin Hydrochloride|Etoposide|Prednisone|Vincristine Sulfate	Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma	A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults	LYMPH|HL|MLYM|RBL|CHL
NCT02176967	3	Ganglioneuroblastoma|Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma	Carboplatin|Cyclophosphamide|Doxorubicin Hydrochloride|Etoposide	Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma	GNBL|MT|NBL|ES|EPIS
NCT02178722	1/Phase 2	Colorectal Cancer (CRC)|Endometrial Cancer|Head and Neck Cancer|Hepatocellular Carcinoma (HCC)|Gastric Cancer|Lung Cancer|Lymphoma|Renal Cell Carcinoma (RCC)|Ovarian Cancer|Solid Tumors|UC (Urothelial Cancer)|Breast Cancer|Melanoma	MK-3475|INCB024360	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)	A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)	CCOV|HCC|CHOL|LUNG|LUSC|EOV|OOVC|NSCLC|EMBC|MT|LGSOC|RCC|LUAS|SCLC|SOC|MEL|NSCLCPD|STOMACH|HGSOC|IMMC|MBC|BREAST|HEAD_NECK|MOV|CSCLC|MLYM|MMBC|IBC|UCEC|LCLC|BRCA|ACBC
NCT02180867	2/Phase 3	Adult Fibrosarcoma|Alveolar Soft Part Sarcoma|Angiomatoid Fibrous Histiocytoma|Atypical Fibroxanthoma|Clear Cell Sarcoma of Soft Tissue|Epithelioid Malignant Peripheral Nerve Sheath Tumor|Epithelioid Sarcoma|Extraskeletal Myxoid Chondrosarcoma|Extraskeletal Osteosarcoma|Fibrohistiocytic Neoplasm|Glomus Tumor of the Skin|Inflammatory Myofibroblastic Tumor|Intimal Sarcoma|Leiomyosarcoma|Liposarcoma|Low Grade Fibromyxoid Sarcoma|Low Grade Myofibroblastic Sarcoma|Malignant Cutaneous Granular Cell Tumor|Malignant Peripheral Nerve Sheath Tumor|Malignant Triton Tumor|Mesenchymal Chondrosarcoma|Myxofibrosarcoma|Myxoid Chondrosarcoma|Myxoinflammatory Fibroblastic Sarcoma|Nerve Sheath Neoplasm|PEComa|Pericytic Neoplasm|Plexiform Fibrohistiocytic Tumor|Sclerosing Epithelioid Fibrosarcoma|Stage IB Soft Tissue Sarcoma AJCC v7|Stage IIB Soft Tissue Sarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Synovial Sarcoma|Undifferentiated (Embryonal) Sarcoma|Undifferentiated High Grade Pleomorphic Sarcoma of Bone	Doxorubicin Hydrochloride|Ifosfamide|Pazopanib Hydrochloride	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)	SKIN|EMCHS|UESL|CHOL|LGFMS|MPNST|ASPS|NST|OS|MCHS|INTS|PECOMA|MYCHS|CCS|SEF|LMS|IMT|MCHSCNS|ES|TISSUE|EPIS|BONE|AFX|CHS|FIBS|SOFT_TISSUE|AFH|LIPO|GCT|SYNS|MFS
NCT02193282	3	ALK Gene Rearrangement|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7	Erlotinib Hydrochloride	Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)	Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)	CHOL|LUNG|NSCLC|MT|SCLC
NCT02194738	3	Large Cell Lung Carcinoma|Lung Adenocarcinoma|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage IB Squamous Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage II Squamous Cell Lung Carcinoma AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIA Squamous Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Squamous Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Squamous Cell Lung Carcinoma AJCC v7	Crizotinib|Erlotinib Hydrochloride	Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)	CHOL|LUSC|LUNG|NSCLC|MT|SCLC|LUAD|LCLC
NCT02201992	3	ALK Gene Rearrangement|ALK Gene Translocation|ALK Positive|Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7	Crizotinib	Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	CHOL|LUNG|NSCLC|ALKLBCL|MT|SCLC|ALCLALKP
NCT02203695	2	Adenocarcinoma of the Prostate	Enzalutamide	Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy	Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy	PRAD
NCT02228096	2	B-cell Acute Lymphoblastic Leukemia|Relapsed B-cell Acute Lymphoblastic Leukemia|Refractory B-cell Acute Lymphoblastic Leukemia		Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients	A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia	LYMPH
NCT02240238	1/Phase 2	Solid Tumors	NC-6004|Gemcitabine	Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer	A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer	
NCT02285439	1/Phase 2	Low-Grade Gliomas|Malignant Neoplasms, Brain|Soft Tissue Neoplasms	MEK162	Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors	Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors	MT|TISSUE|SOFT_TISSUE|SYNS
NCT02289144	2	Metastatic Anaplastic Thyroid Cancer|Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer	Ceritinib	Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer	Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer	THAP|WDTC|MT|THYROID
NCT02303821	1	Acute Lymphoblastic Leukemia (ALL)	Carfilzomib|Dexamethasone|Mitoxantrone|PEG-asparaginase|Vincristine|Intrathecal (IT) Methotrexate|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|6-Mercaptopurine|Cyclophosphamide|Cytarabine|Daunorubicin	Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia	Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia	LYMPH
NCT02306161	3	Metastatic Ewing Sarcoma|Metastatic Malignant Neoplasm in the Bone|Metastatic Malignant Neoplasm in the Bone Marrow|Metastatic Malignant Neoplasm in the Lung|Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone|Peripheral Primitive Neuroectodermal Tumor of Soft Tissues	Cyclophosphamide|Doxorubicin Hydrochloride|Etoposide|Ifosfamide|Vincristine Sulfate	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma	Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma	LUNG|MT|ES|TISSUE|EPIS|BONE|PNET|SOFT_TISSUE|SYNS
NCT02332668	1/Phase 2	Melanoma|Lymphoma|Solid Tumor|Classical Hodgkin Lymphoma|Microsatellite-instability-high Solid Tumor		A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)	A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)	MEL|CHL|MLYM
NCT02339740	3	Acute Promyelocytic Leukemia With PML-RARA	Arsenic Trioxide|Cytarabine|Dexamethasone|Idarubicin|Mitoxantrone Hydrochloride|Tretinoin	Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia	A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid	CML
NCT02354586	2	Ovarian Cancer	Niraparib	A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens	CCOV|EOV|OOVC|MT|LGSOC|SOC|HGSOC|MOV
NCT02357836	Early 1	Non-small Cell Lung Cancer	Itraconazole	Neoadjuvant Itraconazole in Non-small Cell Lung Cancer	Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer	LUNG|NSCLC|MT|SCLC|NSCLCPD
NCT02392429	2	Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia	Chemotherapy|Cytarabine	FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia	Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging	CML|MYELOID|AML
NCT02398773	2	Estrogen Receptor Positive|HER2/Neu Negative|Progesterone Receptor Negative|Progesterone Receptor Positive|Stage IV Breast Cancer AJCC v6 and v7	F-18 16 Alpha-Fluoroestradiol	FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy	[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer	CHOL|MT|ES|EPIS|BREAST
NCT02401542	1/Phase 2	Locally Advanced or Metastatic Urothelial Cell Carcinoma|Urinary Bladder Disease|Urological Diseases	Vofatamab|Docetaxel|Placebo	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma	A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy	MT|ES|EPIS|BLADDER
NCT02407054	2	Prostate Cancer Metastatic	LY3023414|Enzalutamide|Placebo	A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer	A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer	PROSTATE|MT
NCT02411448	3	Metastatic Non-Small Cell Lung Cancer	Ramucirumab|Placebo|Erlotinib|Gefitinib|Osimertinib	A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer	LUNG|NSCLC|MT|SCLC
NCT02424617	1/Phase 2	Non-Small Cell Lung Cancer	erlotinib|BGB324	A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer	NSCLC
NCT02445391	3	Estrogen Receptor Negative|HER2/Neu Negative|Invasive Breast Carcinoma|Progesterone Receptor Negative|Stage II Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Triple-Negative Breast Carcinoma	Capecitabine|Carboplatin|Cisplatin	Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy	A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy	MT|ES|EPIS|BREAST|BRCA
NCT02450331	3	Carcinoma, Transitional Cell	Atezolizumab	A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection	A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection	MT
NCT02465060	2	Advanced Malignant Solid Neoplasm|Bladder Carcinoma|Breast Carcinoma|Cervical Carcinoma|Colon Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Esophageal Carcinoma|Gastric Carcinoma|Glioma|Head and Neck Carcinoma|Kidney Carcinoma|Liver and Intrahepatic Bile Duct Carcinoma|Lung Carcinoma|Lymphoma|Malignant Uterine Neoplasm|Melanoma|Ovarian Carcinoma|Pancreatic Carcinoma|Plasma Cell Myeloma|Prostate Carcinoma|Rectal Carcinoma|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Cervical Carcinoma|Recurrent Colon Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Glioma|Recurrent Head and Neck Carcinoma|Recurrent Liver Carcinoma|Recurrent Lung Carcinoma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Pancreatic Carcinoma|Recurrent Plasma Cell Myeloma|Recurrent Prostate Carcinoma|Recurrent Rectal Carcinoma|Recurrent Skin Carcinoma|Recurrent Thyroid Gland Carcinoma|Recurrent Uterine Corpus Carcinoma|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Plasma Cell Myeloma|Skin Carcinoma|Thyroid Gland Carcinoma|Uterine Corpus Cancer	Adavosertib|Afatinib|Binimetinib|Capivasertib|Crizotinib|Dabrafenib|Dasatinib|Defactinib|FGFR Inhibitor AZD4547|Larotrectinib|Osimertinib|Palbociclib|PI3K-beta Inhibitor GSK2636771|Sapanisertib|Sunitinib Malate|Taselisib|Trametinib|Vismodegib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Molecular Analysis for Therapy Choice (MATCH)	KIDNEY|ODG|DIFG|GB|DCIS|GNOS|MDLC|CHGL|THHC|LUNG|MSCC|GBC|COM|MT|UCP|LUAS|ECAD|PHC|ES|BCC|AGNG|THYROID|LGGNOS|MASCC|THPA|HEAD_NECK|SRCBC|MLYM|MMBC|MCC|IBC|LCLC|LIVER|DIPG|ANGL|GNG|BRCA|SKIN|THAP|LYMPH|SCGBC|SUBE|WDTC|PROSTATE|ENCG|IHCH|LUSC|LCIS|OAST|SPC|UTERUS|OHNCA|BRSRCC|NSCLC|PCM|CCLC|HGGNOS|SCLC|MASC|MEL|DIG|EPIS|HTAT|THPD|THFO|STOMACH|IMMC|ILC|MBC|LECLC|CCHM|THME|AOAST|BREAST|PGNG|CSCLC|BLADDER|MCCE|RLCLC|CSCC|MXOV|IDC|UCEC|AODG|ACBC|USTAD
NCT02466971	2	Cervical Adenocarcinoma|Cervical Adenosquamous Carcinoma|Cervical Squamous Cell Carcinoma, Not Otherwise Specified|Stage IB2 Cervical Cancer AJCC v6 and v7|Stage II Cervical Cancer AJCC v7|Stage II Vaginal Cancer AJCC v6 and v7|Stage IIA Cervical Cancer AJCC v7|Stage IIB Cervical Cancer AJCC v6 and v7|Stage III Vaginal Cancer AJCC v6 and v7|Stage IIIB Cervical Cancer AJCC v6 and v7|Stage IVA Cervical Cancer AJCC v6 and v7|Stage IVA Vaginal Cancer AJCC v6 and v7|Vaginal Adenocarcinoma|Vaginal Adenosquamous Carcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified	Cisplatin|Triapine	Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer	A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	CEAD|MT|CHOL|VA|CESC|OTHER|VSC|CEAS
NCT02477826	3	Non-Small Cell Lung Cancer	Nivolumab|Ipilimumab|Carboplatin|Cisplatin|Gemcitabine|Pemetrexed|Paclitaxel	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	NSCLC
NCT02477878	1	Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Hematologic Neoplasms	AP1903	Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant	A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant	BLLBCRABL1L|BLLIL3IGH|MPALBCRABL1|TLGL|ACML|BLLNOS|MDS|MPALTNOS|TLL|ABL|BLLETV6RUNX1|ETPLL|MPALKMT2A|CMML|MPALBNOS|ATLL|CMML2|BPDCN|BLLRGA|ANKL|BLLHYPO|MLYM|AUL|BLLHYPER|BPLL|AML|BLLBCRABL1|SMMCL|HCL|CMLBCRABL1|TPLL|ALAL|NKCLL|AMML|BLLKMT2A|PERL|CNL|JMML|CML|MLADS|BLLIAMP21|PCM|CLLSLL|AMKL|CMML1|CMML0|BLL|AMOL|CELNOS|TAML|HCL-V|BLLTCF3PBX1|SBLU
NCT02484443	2	Metastatic Malignant Neoplasm in the Lung|Metastatic Osteosarcoma|Recurrent Osteosarcoma		Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma	A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma	LUNG|MT|OS
NCT02492711	3	HER-2 Positive Breast Cancer|Metastatic Neoplasm	Capecitabine|Eribulin|Gemcitabine|Vinorelbine	Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer	A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment	MT|BREAST
NCT02495415	2	Peripheral T-cell Lymphoma	Fenretinide	Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas	Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)	MLYM|MTNN|LYMPH|NPTLTFH|PTCL
NCT02498951	2	CD20 Positive|Central Nervous System B-Cell Non-Hodgkin Lymphoma		Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response	Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders	NHL|MLYM|BRAIN|LYMPH|HL|MBN
NCT02502266	2/Phase 3	Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Serous Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fallopian Tube Undifferentiated Carcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Ovarian Seromucinous Carcinoma|Ovarian Serous Adenocarcinoma|Ovarian Transitional Cell Carcinoma|Ovarian Undifferentiated Carcinoma|Primary Peritoneal Serous Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma	Cediranib Maleate|Olaparib|Paclitaxel|Pegylated Liposomal Doxorubicin Hydrochloride|Topotecan Hydrochloride	Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	OSMCA|CEEN|MT|SOC|EOV
NCT02513667	2	ALK-positive Non-small Cell Lung Cancer	Ceritinib	Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma	Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation in ALK-rearranged Metastatic Lung Adenocarcinoma	LUNG|MT|NSCLC|SCLC
NCT02514031	1	Pancreatic Cancer	ARQ-761|Gemcitabine|nab-paclitaxel	ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer	A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer	MT
NCT02516423	3	Solitary Osseous Plasmacytoma	ixazomib|lenalidomide|dexamethasone|zoledronic acid	Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone	Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	BONE|SYNS
NCT02521493	3	Blasts 5 Percent or More of Bone Marrow Nucleated Cells|Childhood Acute Myeloid Leukemia|Childhood Myelodysplastic Syndrome|Cytopenia|Down Syndrome|Myeloid Leukemia Associated With Down Syndrome|Myeloproliferative Neoplasm|Trisomy 21|Trisomy 21 Mosaicism	Asparaginase|Asparaginase Erwinia chrysanthemi|Cytarabine|Daunorubicin Hydrochloride|Etoposide|Mitoxantrone Hydrochloride|Thioguanine	Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	MDS|RCYC|MPN|AML|MPRDS|MLADS|CML|MYELOID|BONE|SYNS
NCT02524119	2	Hepatocellular Carcinoma	LEE011	LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma	A Phase II Study of LEE011 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma	HCC
NCT02549651	1	Diffuse Large B-Cell Lymphoma	MEDI4736|tremelimumab|AZD9150	MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)	A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma	DLBCLNOS|MLYM|LYMPH|MBN
NCT02554812	2	Advanced Cancer	Avelumab|Utomilumab|PF-04518600|PD 0360324	A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)	A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies	MT
NCT02557854	1	Rhabdomyosarcoma|Neuroblastoma|Sarcoma|Sarcoma, Ewing|Osteosarcoma|Desmoid	Doxorubicin HCl liposomal injection	HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors		SARCNOS|SRCC|UESL|SCCRCC|OCS|MPNST|LGFMS|ASPS|SARCL|RMS|ESST|INTS|DDCHS|MYCHS|LCS|UMLMS|UCP|CCSK|FIOS|IFS|LMS|CELI|LIAS|ES|RCSNOS|MCSL|PLLS|CERMS|SCRMS|UUS|ERMS|PBS|CHS|PT|SECOS|ODGC|CSNOS|MMBC|HDCS|OSOS|HGESS|CHOS|DCS|BA|ULMS|THAP|EMCHS|MS|MRT|CHOL|RAS|SCB|OS|FDCS|PLRMS|SCOS|MCHS|OUSARC|UCS|SCSRMS|MRLS|MCS|CCS|GS|PEOS|ESS|MFH|DFSP|SEF|IMT|MCHSCNS|USARC|NBL|IDCS|EPIS|LGESS|ARMS|UELMS|WDLS|FIBS|MPT|DDCHDM|LGCOS|UAS|ANGS|HGSOS|TEOS|DDLS|GSARC|DES|PAOS|LIPO|PTES|EHAE|MFS|SYNS
NCT02559778	2	Neuroblastoma	bortezomib|crizotinib|dasatinib|lapatinib|sorafenib|vorinostat|DFMO	Pediatric Precision Laboratory Advanced Neuroblastoma Therapy	A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma.	NBL
NCT02562443	3	Myelodysplastic Syndrome|MDS|Refractory Anemia With Excess Blasts|RAEB	rigosertib|Any approved or standard-of-care therapy|best supportive care (BSC)|best supportive care (BSC)	Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA	A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent	MDS|MDSRSSLD|ES|MDSSLD|MDSMPNRST|MDSRSMD|MDSMPNU|MDSU|MDSEB|MDSRS|ESS|MDSEB2|EPIS|MDSID5Q|MDSMD|SYNS|MDSEB1
NCT02562755	3	Hepatocellular Carcinoma (HCC)	Sorafenib	Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone	A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy	MT|HCC|CHOL
NCT02567435	3	Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Untreated Childhood Rhabdomyosarcoma	Cyclophosphamide|Irinotecan Hydrochloride|Temsirolimus|Vincristine Sulfate	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	RMS|SCRMS|ERMS|SCSRMS|ARMS
NCT02568267	2	Breast Cancer|Cholangiocarcinoma|Colorectal Cancer|Head and Neck Neoplasms|Lymphoma, Large-Cell, Anaplastic|Melanoma|Neuroendocrine Tumors|Non-Small Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Papillary Thyroid Cancer|Primary Brain Tumors|Renal Cell Carcinoma|Sarcomas|Salivary Gland Cancers|Adult Solid Tumor	Entrectinib	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	CCOV|MT|RCC|SOC|LMS|HGSOC|THPA|MOV|HEAD_NECK|MLYM|MMBC|IBC|SWDNET|BRCA|GINET|LYMPH|CHOL|EOV|OOVC|NSCLC|PBT|EMBC|LGSOC|MEL|IMMC|MBC|BREAST|SACA|GINETES|ACBC
NCT02572453	2	ALK Positive|BCL6 Positive|Recurrent Anaplastic Large Cell Lymphoma|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Anaplastic Large Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma	Onalespib	Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	ALCLALKP|MLYM|LYMPH|ALKLBCL|ALCL|MCL|MBN
NCT02576990	2	Mediastinal Large B-cell Lymphoma|Richter Syndrome		Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)	A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)	PMBL|MLYM|LYMPH|DIA|MBN
NCT02580448	1/Phase 2	Cancer of the Breast|Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer|Male Breast Cancer|Triple Negative Breast Cancer|ER+ Breast Cancer	Seviteronel	CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)	A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer	MT|MMBC|IBC|BRCA|EMBC|IMMC|MBC|BREAST|ACBC
NCT02584478	1/Phase 2	Endometrial Carcinoma|Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma|Cervical Carcinoma	AL3818|Carboplatin|Paclitaxel	Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)	MT|ECAD|MCCE|MXOV|UCEC
NCT02595424	2	Gastric Neuroendocrine Carcinoma|Intestinal Neuroendocrine Carcinoma|Pancreatic Neuroendocrine Carcinoma	Capecitabine|Carboplatin|Cisplatin|Etoposide|Temozolomide	Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery	Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas	MT|ES|EPIS|STOMACH|HGNEC
NCT02595944	3	Stage IB Non-Small Cell Lung Carcinoma AJCC v7|Stage II Non-Small Cell Lung Cancer AJCC v7|Stage IIA Non-Small Cell Lung Carcinoma AJCC v7|Stage IIB Non-Small Cell Lung Carcinoma AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7		Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers	LUNG|MT|CHOL|NSCLC|SCLC
NCT02596503	1	Relapsed Solid Tumors|Refractory Solid Tumors	Eribulin|Irinotecan	A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors	A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors	
NCT02598661	3	Myelodysplastic Syndromes	Imetelstat|Placebo	Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)	A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment	MDS
NCT02601937	1	Rhabdoid Tumors|INI1-negative Tumors|Synovial Sarcoma|Malignant Rhabdoid Tumor of Ovary	Tazemetostat	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma	OVARY|MRT|SYNS
NCT02617589	3	Brain Cancer	Nivolumab|Temozolomide	An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)	MT
NCT02631876	3	Epithelial Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Ovarian Cancer	IMGN853|Paclitaxel|Doxorubicin|Topotecan	PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer	FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer	CCOV|MT|SOC|HGSOC|MOV|EOV|HGSFT|OOVC|LGSOC
NCT02632708	1	Newly Diagnosed Acute Myeloid Leukemia (AML)|Untreated AML|AML Arising From Myelodysplastic Syndrome (MDS)|AML Arising From Antecedent Hematologic Disorder (AHD)|AML Arising After Exposure to Genotoxic Injury	AG-120|AG-221|cytarabine|daunorubicin|idarubicin|mitoxantrone|etoposide	Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation	A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation	MDS|AML|CML|MYELOID|DIA
NCT02637687	1/Phase 2	Neoplasms|Central Nervous System Neoplasms	LOXO-101 (larotrectinib)	Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors	A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors	MDS/MPN|MLNPCM1JAK2|BFN|TMN|MLNFGFR1|MNGT|MPN|MLNPDGFRB|BRAIN|PRNET|DCS|MTNN|MPNU|MLNPDGFRA|MNGLP|MLNER|MBN
NCT02655822	1	Non-Small Cell Lung Cancer|Malignant Melanoma|Renal Cell Cancer|Triple Negative Breast Cancer|Colorectal Cancer|Bladder Cancer|Metastatic Castration Resistant Prostate Cancer	CPI-444|CPI-444|CPI-444|CPI-444 + atezolizumab|CPI-444	Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers	A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers	GBC|MT|RCC|SCBC|ES|PROSTATE|NSCLC|MEL|EPIS|BREAST|BLADDER
NCT02659020	1/Phase 2	Soft Tissue Sarcoma	Olaratumab|Gemcitabine|Docetaxel|Placebo	A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma	A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma	SOFT_TISSUE|MFH|TISSUE|SYNS
NCT02664961	2	Gestational Trophoblastic Neoplasia|Choriocarcinoma|Placental Site Trophoblastic Tumor|Epithelioid Trophoblastic Tumor	TRC105|Bevacizumab	Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)	A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)	MT|ES|UCCA|ETT|BCCA|GTD|EPIS|OCNOS|TCCA|PSTT
NCT02667587	3	Brain Neoplasms	Nivolumab|Temozolomide	An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)	A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma	
NCT02667873	1	Solid Tumors	SL-801	A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors	A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors	
NCT02674568	2	Small Cell Lung Cancer	Rovalpituzumab tesirine	Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)	An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)	SCLC
NCT02677116	1	Neoplasm Metastasis	Olaratumab|Doxorubicin|Vincristine|Irinotecan|Ifosfamide	A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer	A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors	
NCT02677922	1/Phase 2	Leukemia, Myeloid, Acute	AG-120|Azacitidine|AG-221	A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)	A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy	MYELOID
NCT02679144	2	Neuroblastoma	Difluoromethylornithine (DFMO)	Neuroblastoma Maintenance Therapy Trial	NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)	NBL
NCT02684058	2	Diffuse Astrocytoma|Anaplastic Astrocytoma|Astrocytoma|Oligodendroglioma, Childhood|Anaplastic Oligodendroglioma|Glioblastoma|Pilocytic Astrocytoma|Giant Cell Astrocytoma|Pleomorphic Xanthoastrocytoma|Anaplastic Pleomorphic Xanthoastrocytoma|Angiocentric Glioma|Chordoid Glioma of Third Ventricle|Gangliocytoma|Ganglioglioma|Anaplastic Ganglioglioma|Dysplastic Gangliocytoma of Cerebrellum|Desmoplastic Infantile Astrocytoma and Ganglioglioma|Papillary Glioneuronal Tumor|Rosette-forming Glioneurona Tumor|Central Neurocytoma|Extraventricular Neurocytoma|Cerebellar Iponeurocytoma	dabrafenib|trametinib|Carboplatin with vincristine	Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG	Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)	ODG|GB|ASTR|CHGL|PGNT|ES|AGNG|PXA|AASTR|CNC|ANGL|GNG|DASTR|EVN|PAST|DIA|APXA|EPIS|GNC|AODG
NCT02684461	2	Non Small Cell Lung Cancer	Pembrolizumab	Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel	Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel After Standard First-Line Induction Chemotherapy in Advanced NSCLC	LUNG|MT|NSCLC|SCLC
NCT02688608	2	Anaplastic Thyroid Cancer	Pembrolizumab	Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer	Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer	THAP
NCT02703272	3	Lymphoma, Non-Hodgkin	Ibrutinib|Rituximab|Ifosfamide|Carboplatin|Etoposide|Vincristine|Idarubicin|Dexamethasone	A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma	A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma	MLYM|LYMPH
NCT02706626	2	Non-Small Cell Lung Cancer	brigatinib	Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors	Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)	NSCLC
NCT02715284	1	Advanced or Metastatic Solid Tumors		A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors	
NCT02717507	2	Cancer Survivor	Carvedilol	Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors	Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial	MT
NCT02719574	1/Phase 2	Acute Myeloid Leukemia|Acute Myelogenous Leukemia|Myelodysplastic Syndrome	FT-2102|Azacitidine|Cytarabine	Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation	A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation	MDS|AML
NCT02724579	2	Medulloblastoma|Untreated Childhood Medulloblastoma	Cisplatin|Cyclophosphamide|Lomustine|Vincristine Sulfate	Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	MBL
NCT02725268	2	Endometrial Neoplasms	Paclitaxel|MLN0128|MLN1117	Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer	A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3KÎ± Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer	
NCT02728258	2	Endometrial Endometrioid Adenocarcinoma|Endometrial Mixed Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Undifferentiated Carcinoma|Metastatic Endometrioid Adenocarcinoma|PIK3CA Gene Mutation|Recurrent Uterine Corpus Carcinoma	Copanlisib	Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer	A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	USC|UEC|CEEN|MT|UTERUS
NCT02729298	1	Advanced Solid Tumors|EGFR Positive Non-small Cell Lung Cancer|Colorectal Carcinoma|Recurrent Ovarian Carcinoma|BRAF-Mutated Melanoma	TP-0903	First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors	A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors	LUNG|MT|NSCLC|SCLC|MEL
NCT02734537	2	Head and Neck Squamous Cell Carcinoma|Hypopharyngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma|Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant|Lip and Oral Cavity Squamous Cell Carcinoma|p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Lip and Oral Cavity Cancer AJCC v8|Stage III Oral Cavity Verrucous Carcinoma|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IVA Hypopharyngeal Carcinoma AJCC v8|Stage IVA Laryngeal Cancer AJCC v8|Stage IVA Lip and Oral Cavity Cancer AJCC v8|Stage IVA Oral Cavity Verrucous Carcinoma|Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8	Cisplatin	Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery	Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing	MT|HNSC|HPHSC|OCSC|CHOL|LXSC
NCT02741570	3	Head and Neck Cancer	Cetuximab/Erbitux|Cisplatin/Platinol|Carboplatin/Paraplatin|Fluorouracil/Adrucil	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	MT|HEAD_NECK
NCT02748135	1/Phase 2	Relapsed or Refractory Medulloblastoma (MB) (Part A: Also Include Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS))	TB-403 20mg/kg|TB-403 50mg/kg|TB-403 100mg/kg|TB-403 â¤175mg/kg	A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma	A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma	RMS|ES|MBL|NBL|EPIS|ARMS
NCT02773849	3	Superficial Bladder Cancer		A Study to Evaluate INSTILADRIN® in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC	A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)	MT|BLADDER
NCT02781506	2	Metastatic Clear Cell Renal Cell Carcinoma	Nivolumab	Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma	Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)	MT|RCC|CCRCC
NCT02793583	2/Phase 3	Diffuse Large B-Cell Lymphoma|Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Mantle Cell Lymphoma	TGR-1202 + Ublituximab|TGR-1202|TGR-1202 + Ublituximab + Bendamustine	Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma	A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma	DLBCLNOS|MZL|MLYM|LYMPH|MCL|CLLSLL|FL|MBN
NCT02811783	3	Mycosis Fungoides|Lymphoma, T-Cell, Cutaneous|Sézary Syndrome	Naloxone Hydrochloride Lotion, 0.5%|Placebo Lotion	Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL	A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma	MLYM|LYMPH|MYCF
NCT02817113	1	Head and Neck Neoplasms	NC-6004|Cetuximab|5-FU	Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer	Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	HEAD_NECK
NCT02828358	2	Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|KMT2A Gene Rearrangement|Mixed Phenotype Acute Leukemia	Azacitidine|Cyclophosphamide|Cytarabine|Daunorubicin Hydrochloride|Dexamethasone|Hydrocortisone Sodium Succinate|Leucovorin Calcium|Mercaptopurine|Methotrexate|Pegaspargase|Prednisolone|Thioguanine|Vincristine Sulfate	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement	MPALBCRABL1|MPALTNOS|MPALKMT2A|MPALBNOS|LYMPH
NCT02834013	2	Acinar Cell Carcinoma|Adenoid Cystic Carcinoma|Adrenal Cortex Carcinoma|Adrenal Gland Pheochromocytoma|Anal Canal Neuroendocrine Carcinoma|Anal Canal Undifferentiated Carcinoma|Appendix Mucinous Adenocarcinoma|Bartholin Gland Transitional Cell Carcinoma|Bladder Adenocarcinoma|Cervical Adenocarcinoma|Cholangiocarcinoma|Chordoma|Colorectal Squamous Cell Carcinoma|Desmoid-Type Fibromatosis|Endometrial Transitional Cell Carcinoma|Endometrioid Adenocarcinoma|Esophageal Neuroendocrine Carcinoma|Esophageal Undifferentiated Carcinoma|Extrahepatic Bile Duct Carcinoma|Fallopian Tube Adenocarcinoma|Fallopian Tube Transitional Cell Carcinoma|Fibromyxoid Tumor|Gastric Neuroendocrine Carcinoma|Gastric Squamous Cell Carcinoma|Gastric Undifferentiated Carcinoma|Gastrointestinal Stromal Tumor|Giant Cell Carcinoma|Intestinal Neuroendocrine Carcinoma|Intrahepatic Cholangiocarcinoma|Lung Carcinoid Tumor|Lung Sarcomatoid Carcinoma|Major Salivary Gland Carcinoma|Malignant Odontogenic Neoplasm|Malignant Peripheral Nerve Sheath Tumor|Malignant Testicular Sex Cord-Stromal Tumor|Metaplastic Breast Carcinoma|Metastatic Malignant Neoplasm of Unknown Primary Origin|Minimally Invasive Lung Adenocarcinoma|Mixed Mesodermal (Mullerian) Tumor|Mucinous Adenocarcinoma|Mucinous Cystadenocarcinoma|Nasal Cavity Adenocarcinoma|Nasal Cavity Carcinoma|Nasopharyngeal Carcinoma|Nasopharyngeal Papillary Adenocarcinoma|Nasopharyngeal Undifferentiated Carcinoma|Oral Cavity Carcinoma|Oropharyngeal Undifferentiated Carcinoma|Ovarian Adenocarcinoma|Ovarian Germ Cell Tumor|Ovarian Mucinous Adenocarcinoma|Ovarian Squamous Cell Carcinoma|Ovarian Transitional Cell Carcinoma|Pancreatic Acinar Cell Carcinoma|Pancreatic Neuroendocrine Carcinoma|Paraganglioma|Paranasal Sinus Adenocarcinoma|Paranasal Sinus Carcinoma|Parathyroid Gland Carcinoma|Pituitary Gland Carcinoma|Placental Choriocarcinoma|Placental-Site Gestational Trophoblastic Tumor|Primary Peritoneal High Grade Serous Adenocarcinoma|Pseudomyxoma Peritonei|Rare Disorder|Scrotal Squamous Cell Carcinoma|Seminal Vesicle Adenocarcinoma|Seminoma|Serous Cystadenocarcinoma|Small Intestinal Adenocarcinoma|Small Intestinal Squamous Cell Carcinoma|Spindle Cell Neoplasm|Squamous Cell Carcinoma of the Penis|Teratoma With Malignant Transformation|Testicular Non-Seminomatous Germ Cell Tumor|Thyroid Gland Carcinoma|Tracheal Carcinoma|Transitional Cell Carcinoma|Ureter Adenocarcinoma|Ureter Squamous Cell Carcinoma|Urethral Adenocarcinoma|Urethral Squamous Cell Carcinoma|Vaginal Adenocarcinoma|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified|Vulvar Carcinoma		Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	OCS|MPNST|THHC|CEAD|LUNG|SARCL|UAD|CEEN|MT|PHC|NSGCT|ES|UTUC|THYROID|OFMT|NPC|ACC|THPA|PTCA|LUAD|ODGC|GCLC|SNSC|THAP|VULVA|CHOL|SEM|VA|WDTC|IHCH|BCCA|MAAP|OTHER|BLCA|CHDM|PSCC|GIST|EPIS|PAAC|THPD|THFO|STOMACH|VSC|CEMU|MBC|HGNEC|LUCA|BMGT|THME|PGNG|MYXO|ACYC|SACA|PSTT|OGCT|DES|BLAD|TT|USCC|TMT|ACCC|USTAD
NCT02851407	3	Veno-occlusive Disease	Defibrotide	Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients	A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant	CHOL
NCT02853305	3	Urothelial Carcinoma Associated 1 RNA, Human	Cisplatin|Carboplatin|Gemcitabine	Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)	A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma	MT|SYNS
NCT02853604	3	High Risk Cervical Cancer|Advanced Cervical Cancer	ADXS11-001|Placebo	Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer	Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV	MT
NCT02855125	2	Advanced or Metastatic Non-small Cell Lung Cancer	TAS-114|S-1	A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1	A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer	LUNG|MT|NSCLC|SCLC
NCT02867592	2	Adrenal Cortex Carcinoma|Adult Alveolar Soft Part Sarcoma|Adult Clear Cell Sarcoma of Soft Parts|Adult Hepatocellular Carcinoma|Adult Rhabdomyosarcoma|Adult Soft Tissue Sarcoma|Childhood Alveolar Soft Part Sarcoma|Childhood Central Nervous System Neoplasm|Childhood Clear Cell Sarcoma of Soft Parts|Childhood Hepatocellular Carcinoma|Childhood Rhabdomyosarcoma|Childhood Soft Tissue Sarcoma|Childhood Solid Neoplasm|Ewing Sarcoma|Hepatoblastoma|Hepatocellular Carcinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adult Hepatocellular Carcinoma|Recurrent Adult Soft Tissue Sarcoma|Recurrent Alveolar Soft Part Sarcoma|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Hepatocellular Carcinoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma|Recurrent Hepatoblastoma|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Renal Cell Carcinoma|Recurrent Rhabdomyosarcoma|Refractory Osteosarcoma|Renal Cell Carcinoma|Thyroid Gland Medullary Carcinoma|Wilms Tumor	Cabozantinib S-malate	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors	ASPS|RMS|MT|RCC|ES|ACC|SOFT_TISSUE|BRAIN|HCC|OS|LIHB|CCS|TISSUE|THME|SYNS
NCT02879643	1	ALL, Childhood|Lymphoblastic Leukemia, Acute, Childhood|Lymphoblastic Leukemia, Acute	Marqibo in combination with UK ALL R3	Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL	A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia	LYMPH
NCT02883049	3	B Acute Lymphoblastic Leukemia|Central Nervous System Leukemia|Ph-Like Acute Lymphoblastic Leukemia|Testicular Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia	Clofarabine|Cyclophosphamide|Cytarabine|Dasatinib|Daunorubicin Hydrochloride|Dexamethasone|Doxorubicin Hydrochloride|Etoposide|Hydrocortisone Sodium Succinate|Leucovorin Calcium|Mercaptopurine|Methotrexate|Pegaspargase|Prednisone|Thioguanine|Vincristine Sulfate	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations	A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations	ES|BRAIN|LYMPH|EPIS
NCT02892201	2	Head and Neck Squamous Cell Carcinoma	Pembrolizumab	Pembrolizumab in HNSCC With Residual Disease After Radiation	A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation	HNSC
NCT02893930	2	Pancreatic Neuroendocrine Tumor G1|Pancreatic Neuroendocrine Tumor G2|Refractory Pancreatic Neuroendocrine Carcinoma	Sapanisertib	Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery	A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)	PANET|MT
NCT02899195	2	Mesothelioma|Pleural Mesothelioma	Concurrent Durvalumab|Maintenance Durvalumab	Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma	Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma	TMESO|PLSMESO|PLMESO|SFT|ES|PLEMESO|PLBMESO|PEMESO|EPIS
NCT02902484	1/Phase 2	Cancer of Pancreas	Nintedanib	Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer	A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer	MT|PANCREAS
NCT02912559	3	Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Stage III Colon Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7	Atezolizumab|Fluorouracil|Leucovorin Calcium|Oxaliplatin	Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	MT|CHOL|COAD
NCT02913261	3	Corticosteroid Refractory Acute Graft vs Host Disease	Ruxolitinib|Best Available Therapy (BAT)	Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation	A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation	
NCT02922777	1	Non-Small Cell Lung Carcinoma	BGB324|Docetaxel	Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.	Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)	NSCLC
NCT02924376	2	Cholangiocarcinoma	INCB054828	Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy	A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy	CHOL
NCT02927769	2	Hodgkin Disease		A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment	Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)	HL
NCT02947347	3	Treatment Naive Follicular Lymphoma	ibrutinib|placebo to match ibrutinib|rituximab|ibrutinib|placebo to match ibrutinib|placebo to match ibrutinib	Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)	MLYM|LYMPH|FL
NCT02952534	2	Metastatic Castration Resistant Prostate Cancer	Rucaparib	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency	TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency	MT|ES|PROSTATE|EPIS
NCT02981628	2	Childhood B Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Refractory Childhood Acute Lymphoblastic Leukemia		Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia	A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)	LYMPH
NCT02989857	3	Advanced Cholangiocarcinoma|Metastatic Cholangiocarcinoma	AG-120|AG-120 matched placebo	Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation	MT|CHOL
NCT03007147	3	B Acute Lymphoblastic Leukemia|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia	Cyclophosphamide|Cytarabine|Daunorubicin Hydrochloride|Dexamethasone|Dexrazoxane Hydrochloride|Doxorubicin|Etoposide|Ifosfamide|Imatinib Mesylate|Leucovorin Calcium|Mercaptopurine|Mercaptopurine|Methotrexate|Methylprednisolone|Pegaspargase|Prednisolone|Therapeutic Hydrocortisone|Thioguanine|Vincristine Sulfate	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones	ES|LYMPH|ESS|EPIS|SYNS
NCT03013998	1/Phase 2	Previously Untreated Acute Myeloid Leukemia	Daunorubicin (BAML-16-001-S1)|Cytarabine (BAML-16-001-S1)|Azacitidine (BAML-16-001-S2)|AG-221 (BAML-16-001-S3)|Azacitidine (BAML-16-001-S3)|Entospletinib (BAML-16-001-S4)|Azacitidine (BAML-16-001-S4)|Entospletinib (BAML-16-001-S5)|Decitabine (BAML-16-001-S5)|Entospletinib (BAML-16-001-S6)|Azacitidine (BAML-16-001-S6)|Daunorubicin (BAML-16-001-S6)|Cytarabine (BAML-16-001-S6)|Pevonedistat (BAML-16-001-S9)|Azacitidine (BAML-16-001-S9)|AG-120 (BAML-16-001-S16)|Azacitidine (BAML-16-001-S16)	Study of Biomarker-Based Treatment of Acute Myeloid Leukemia	A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	AML|CML|MYELOID
NCT03024996	3	Renal Cell Carcinoma	Atezolizumab	A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy	A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (AntiâPD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy	RCC
NCT03029585	2	Ovarian Carcinoma	NanoPac® 100 mg/m2|NanoPac® 200 mg/m2|NanoPac® 300 mg/m2|NanoPac® 400 mg/m2|Standard of Care Intravenous Chemotherapy	Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer	Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery	MT|MXOV
NCT03033511	3	Small Cell Lung Cancer	Placebo for dexamethasone|Placebo for rovalpituzumab tesirine|Rovalpituzumab tesirine|Dexamethasone	A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)	SCLC
NCT03033576	2	Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7		Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery	A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent	SKCM|CHOL|MEL
NCT03036488	3	Triple Negative Breast Neoplasms	Carboplatin|Paclitaxel|Doxorubicin|Epirubicin|Cyclophosphamide|Placebo	Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)	A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)	BREAST
NCT03038100	3	Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms	Paclitaxel|Carboplatin|Atezolizumab|Bevacizumab|Atezolizumab Placebo	A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	CCOV|MT|SOC|HGSOC|MOV|EOV|HGSFT|OOVC|LGSOC
NCT03055013	3	Sarcomatoid Renal Cell Carcinoma|Stage II Renal Cell Cancer AJCC v7|Stage III Renal Cell Cancer AJCC v7|Unclassified Renal Cell Carcinoma		Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy	A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	SRCC|MT|RCC|URCC|CHOL
NCT03061812	3	Small Cell Lung Cancer	Rovalpituzumab tesirine|Topotecan	Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)	A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)	SCLC
NCT03065179	2	Kidney Cancer Metastatic|Kidney Cancer|Kidney Cancer, Stage IV	Nivolumab/Ipilimumab	Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients	Phase II Trial of Stereotactic Body Radiation Therapy in Combination With Nivolumab Plus Ipilimumab in Patients With Metastatic Renal Cell Cancer	KIDNEY|MT
NCT03065712	2	Breast Cancer	F-18 Fluoroestradiol	Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET	Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET and Predictive Measure for Endocrine Therapy Response in Patients With Newly Diagnosed Metastatic Breast Cancer	MT|MMBC|IBC|BRCA|EMBC|IMMC|MBC|BREAST|ACBC
NCT03067181	3	Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor	Bleomycin|Carboplatin|Cisplatin|Etoposide	Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors	MT|EMBCA|TYST|ES|CHOL|BCCA|OIMT|OYST|EPIS|OEC|OMT|TCCA|TT
NCT03067610	2	Head and Neck Cancer|Carcinoma, Squamous Cell|Neoplasms, Oral|Neoplasms, Pharyngeal	chemotherapy	Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer	A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy	MT|HEAD_NECK
NCT03070886	2/Phase 3	Stage I Prostate Adenocarcinoma|Stage II Prostate Adenocarcinoma|Stage III Prostate Adenocarcinoma	Bicalutamide|Docetaxel|Flutamide|Goserelin Acetate|Leuprolide Acetate|Nilutamide	Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery	Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel	MT|PRAD|PROSTATE
NCT03072238	3	Metastatic Prostate Cancer	Ipatasertib|Abiraterone|Placebo	Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer	MT|PROSTATE
NCT03077698	2	Endometrial Cancer	Sodium Cridanimod|progestin therapy	An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer	A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma	MT|UCEC
NCT03091660	3	Stage 0 Bladder Urothelial Carcinoma|Stage 0is Bladder Urothelial Carcinoma|Stage I Bladder Urothelial Carcinoma		S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer	S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer	MT|BLCA|BLADDER
NCT03095612	1/Phase 2	Non-small Cell Lung Cancer	Selinexor	Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)	An Investigator-Sponsored, Phase 1/2 Trial of the Oral XPO1 Inhibitor Selinexor (KPT-330) in Combination With Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer (NSCLC)	LUNG|MT|NSCLC|SCLC|NSCLCPD
NCT03101566	2	Biliary Tract Neoplasms	Gemcitabine|Cisplatin|Ipilimumab|Nivolumab	Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer	A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]	BILIARY_TRACT
NCT03110562	3	Multiple Myeloma	Selinexor|Bortezomib|Dexamethasone	Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)	PCM
NCT03117309	2	Advanced Renal Cell Carcinoma	Nivolumab 240 mg|Ipilimumab 1mg/kg|Nivolumab 3mg/kg|Nivolumab 360mg	Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma	Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260	MT|RCC
NCT03126916	3	Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma	Busulfan|Carboplatin|Cisplatin|Crizotinib|Cyclophosphamide|Dexrazoxane Hydrochloride|Doxorubicin Hydrochloride|Etoposide Phosphate|Isotretinoin|Melphalan|Thiotepa|Topotecan Hydrochloride|Vincristine Sulfate	Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma	A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)	GNBL|MT|NBL
NCT03137771	2	Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer	Docetaxel|Gemcitabine|Pemetrexed Disodium	Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer	Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial	LUNG|MT|NSCLC|SCLC
NCT03138499	3	Hodgkin's Disease		A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,	Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)	HL
NCT03141034	2	Gastric Adenocarcinoma|Gastro-esophageal Junction Adenocarcinoma	Irinotecan|Ramucirumab	Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma	Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma	MT|ES|EPIS|STAD
NCT03142334	3	Renal Cell Carcinoma	Placebo (saline solution)	Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)	RCC
NCT03151304	2	Myelodysplastic Syndromes	Pracinostat|Azacitidine	A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes	A Two-Stage, Open-Label Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents	MDS
NCT03155620	2	Advanced Malignant Solid Neoplasm|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma|Childhood Langerhans Cell Histiocytosis|Histiocytic Sarcoma|Juvenile Xanthogranuloma|Malignant Glioma|Recurrent Central Nervous System Neoplasm|Recurrent Childhood Ependymoma|Recurrent Childhood Malignant Germ Cell Tumor|Recurrent Childhood Medulloblastoma|Recurrent Childhood Non-Hodgkin Lymphoma|Recurrent Childhood Rhabdomyosarcoma|Recurrent Childhood Soft Tissue Sarcoma|Recurrent Ewing Sarcoma|Recurrent Glioma|Recurrent Hepatoblastoma|Recurrent Langerhans Cell Histiocytosis|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Recurrent Osteosarcoma|Recurrent Peripheral Primitive Neuroectodermal Tumor|Refractory Central Nervous System Neoplasm|Refractory Childhood Malignant Germ Cell Tumor|Refractory Langerhans Cell Histiocytosis|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Rhabdoid Tumor|Stage III Osteosarcoma AJCC v7|Stage III Soft Tissue Sarcoma AJCC v7|Stage IV Osteosarcoma AJCC v7|Stage IV Soft Tissue Sarcoma AJCC v7|Stage IVA Osteosarcoma AJCC v7|Stage IVB Osteosarcoma AJCC v7|Wilms Tumor	Ensartinib|Erdafitinib|Larotrectinib|Olaparib|Palbociclib|PI3K/mTOR Inhibitor LY3023414|Selumetinib Sulfate|Tazemetostat|Vemurafenib	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	NHL|RMS|HDCN|RBL|ES|JXG|PNET|SOFT_TISSUE|MLYM|BRAIN|HDCS|LCH|LYMPH|MRT|CHOL|OS|LIHB|MBL|NBL|TISSUE|HL|EPM|SYNS
NCT03155997	3	Breast Cancer	Abemaciclib|Standard Adjuvant Endocrine Therapy	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer	A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer	MT|MMBC|IBC|BRCA|EMBC|IMMC|MBC|BREAST|ACBC
NCT03164603	1	Solid Tumor	NLG802	NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors	A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors	
NCT03181126	1	Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma	Navitoclax|Chemotherapy|Venetoclax	A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma	A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma	MLYM|LYMPH
NCT03190915	2	Activating RAS Mutation|Blasts Under 20 Percent of Bone Marrow Nucleated Cells|Blasts Under 20 Percent of Peripheral Blood White Cells|Juvenile Myelomonocytic Leukemia|Monosomy 7|Neurofibromatosis Type 1|NF1 Gene Mutation|PTPN11 Gene Mutation|Splenomegaly	Trametinib	Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	NFIB|JMML|MYELOID|BONE
NCT03215511	1/Phase 2	Carcinoma, Non-Small-Cell Lung|Thyroid Neoplasms|Sarcoma|Colorectal Neoplasms|Salivary Gland Neoplasms|Biliary Tract Neoplasms|Brain Neoplasm, Primary|Melanoma|Glioblastoma|Bile Duct Neoplasms|Astrocytoma|Head and Neck Squamous Cell Carcinoma|Pontine Glioma|Pancreatic Neoplasms|Ovarian Neoplasms|Carcinoma, Renal Cell|Cholangiocarcinoma|Skin Carcinoma|Carcinoma, Bronchogenic|Bronchial Neoplasms|Lung Neoplasms|Respiratory Tract Neoplasms|Thoracic Neoplasms|Neoplasms, Nerve Tissue|Nevi and Melanomas|Intestinal Neoplasms|Thyroid Cancer|GIST|Malignant Peripheral Nerve Sheath Tumors|Breast Secretory Carcinoma|Uterine Neoplasms|Fibrosarcoma|Infantile Fibrosarcoma|Congenital Mesoblastic Nephroma|Central Nervous System Neoplasms	LOXO-195	Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers	A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers	SARCNOS|SRCC|GB|UESL|SCCRCC|OCS|MPNST|LGFMS|ASPS|ASTR|THHC|LUNG|SARCL|RMS|ESST|INTS|DDCHS|MYCHS|MT|RCC|LCS|HNSC|UMLMS|UCP|CCSK|FIOS|IFS|LMS|CELI|LIAS|ES|RCSNOS|BCC|MCSL|PLLS|CERMS|THYROID|SCRMS|UUS|ERMS|PBS|CHS|THPA|PT|SECOS|ODGC|CSNOS|BRAIN|MMBC|MCC|HDCS|OSOS|HGESS|CHOS|PTH|DIPG|DCS|BA|ULMS|SKIN|THAP|EMCHS|MS|MRT|CHOL|RAS|SCB|NST|WDTC|OS|FDCS|UTERUS|PLRMS|SCOS|MCHS|OUSARC|UCS|SCSRMS|MRLS|MCS|CCS|GS|PEOS|ESS|MFH|DFSP|SEF|IMT|MCHSCNS|MEL|USARC|GIST|TISSUE|IDCS|EPIS|LGESS|THPD|THFO|ARMS|UELMS|WDLS|THME|FIBS|BREAST|MPT|DDCHDM|LGCOS|UAS|ANGS|HGSOS|TEOS|DDLS|GSARC|CSCC|BILIARY_TRACT|PAOS|LIPO|PTES|EHAE|MFS|SYNS
NCT03241550	1	Hematological Malignancy	isavuconazonium sulfate - intravenous|isavuconazonium sulfate - oral	A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients	A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients	MT
NCT03245151	1/Phase 2	Recurrent and Refractory Solid Tumors	Lenvatinib|Everolimus	Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors	A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors	
NCT03268954	3	Myelodysplastic Syndrome|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute	Azacitidine|Pevonedistat	Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)	A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia	MDS|MYELOID
NCT03289039	2	Breast Cancer	Neratinib|Fulvestrant	Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer	A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer	MT|MMBC|IBC|BRCA|EMBC|IMMC|MBC|BREAST|ACBC
NCT03298451	3	Hepatocellular Carcinoma	Durvalumab|Tremelimumab (Regimen 1)|Tremelimumab (Regimen 2)|Sorafenib|Durvalumab (Regimen 1)|Durvalumab (Regimen 2)	Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma	A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma	HCC
NCT03303339	1/Phase 2	Acute Myeloid Leukemia	Onvansertib|Cytarabine|Decitabine	Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).	A Phase 1b/2 Study of PCM-075 (Onvansertib) in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)	AML
NCT03306264	3	Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia	ASTX727|Dacogen	Study of ASTX727 vs IV Decitabine in MDS and CMML	A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]	MDS|CMML
NCT03312114	2	Recurrent Epithelial Cancer of Ovary|Primary Peritoneal Carcinoma|Fallopian Tube Cancer	Avelumab	AntiâPD-L1 and SAbR for Ovarian Cancer	Phase II Trial of Concurrent AntiâPD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)	MT|OVARY|HGSFT
NCT03318497	2	Pancreatic Adenocarcinoma	3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma	Initial Evaluation of Role of Early Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma	PAAD
NCT03336216	2	Advanced Pancreatic Cancer	Nab-paclitaxel|Onivyde|Fluorouracil|Gemcitabine|Oxaliplatin|Leucovorin|Irinotecan Hydrochloride	A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer	A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer	MT
NCT03343197	1	Glioma	AG-120|AG881	Study of AG-120 and AG-881 in Subjects With Low Grade Glioma	A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma	ODG|DIFG|GB|GNOS|CHGL|PHC|AGNG|LGGNOS|DIPG|ANGL|GNG|SUBE|ENCG|OAST|HGGNOS|DIG|HTAT|AOAST|PGNG|AODG
NCT03361748	2	Multiple Myeloma		Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)	A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma	PCM
NCT03365882	2	Colon Adenocarcinoma|ERBB2 Gene Amplification|Rectal Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage III Colon Cancer AJCC v7|Stage III Rectal Cancer AJCC v7|Stage IIIA Colon Cancer AJCC v7|Stage IIIA Rectal Cancer AJCC v7|Stage IIIB Colon Cancer AJCC v7|Stage IIIB Rectal Cancer AJCC v7|Stage IIIC Colon Cancer AJCC v7|Stage IIIC Rectal Cancer AJCC v7|Stage IV Colon Cancer AJCC v7|Stage IV Rectal Cancer AJCC v7|Stage IVA Colon Cancer AJCC v7|Stage IVA Rectal Cancer AJCC v7|Stage IVB Colon Cancer AJCC v7|Stage IVB Rectal Cancer AJCC v7	Irinotecan Hydrochloride	S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery	S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification	MT|READ|RBL|CHOL|COAD
NCT03382561	2	Extensive Stage Small Cell Lung Carcinoma	Carboplatin|Cisplatin|Etoposide	Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer	Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)	LUNG|MT|SCLC
NCT03426865	2	Testis Cancer|Germ Cell Tumor|Testicular Cancer|Germ Cell Tumor of Testis|Germ Cell Tumor, Testicular, Childhood|Testicular Neoplasms|Testicular Germ Cell Tumor|Testicular Yolk Sac Tumor|Testicular Choriocarcinoma|Testicular Diseases|Germ Cell Cancer Metastatic|Germ Cell Neoplasm of Retroperitoneum|Germ Cell Cancer, Nos	Axumin PET scan	Role of Axumin PET Scan in Germ Cell Tumor	Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer	PERITONEUM|MT|OMGCT|TYST|NSGCT|ES|MGCT|EGCT|TESTIS|VGCT|EPIS|TCCA|BGCT|OGCT|BMGCT&VMGCT
NCT03441360	2	Relapsed/Refractory Rhabdomyosarcoma|Non-rhabdomyosarcoma Soft Tissue Sarcoma|Ewing Sarcoma	Eribulin mesylate	Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)	A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)	RMS|ES|SOFT_TISSUE|TISSUE|SYNS
NCT03519997	2	Hepatocellular Carcinoma	Pembrolizumab|Bavituximab	A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma	A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma	HCC
NCT03533582	2/Phase 3	Childhood Hepatocellular Carcinoma|Childhood Malignant Liver Neoplasm|Elevated Alpha-Fetoprotein|Hepatoblastoma|SMARCB1 Gene Mutation	Carboplatin|Cisplatin|Doxorubicin|Etoposide|Fluorouracil|Gemcitabine|Irinotecan|Oxaliplatin|Sorafenib|Vincristine Sulfate	Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery	Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)	MT|LIVER|HCC|LIHB
